RATIONALE: Information on the clinical profile of CIU/CSU in adolescents is limited. Baseline characteristics and demographics of an adolescent subgroup of CIU/CSU patients enrolled in randomized, placebo-controlled omalizumab trials are evaluated. METHODS: This is a post-hoc descriptive analysis of pooled baseline data from three omalizumab trials in CIU/CSU patients who remained symptomatic despite H 1 -antihistamine treatment [and H 2 -antihistamines and/or leukotriene receptor antagonists (LTRA) in one study]. Demographics and disease characteristics are summarized for overall and for adolescent patients (> _12 to <18 years). RESULTS: Of 975 patients [mean (standard deviation; SD) age, 42.3 (14.1) years], 39 were adolescents [15.1 (1.5) years]. Most patients were female (overall, 73.4%; adolescents, 69.2%) and white (85.4%; 84.6%), with a mean BMI (SD) of 29.6 (7.3) and 24.4 (4.7) kg/m 2 , respectively. A CU index test (functional anti-FcεR) was positive in 28.5% overall and 17.9% of adolescents. Mean urticaria activity score over 7 days (SD) was 30.9 (6.7) overall and 28.6 (5.7) for adolescents; weekly itch severity score, 14.1 (3.6) and 13.3 (3.4); weekly number of hives score, 16.8 (4.3) and 15.3 (4.0); and Dermatology Life Quality Index overall score, 13.2 (6.5) and 12.0 (5.2), respectively. Overall, patients experienced CIU/ CSU for mean duration (SD) of 6.9 (9.1) years and adolescents for 3.2 (3.7) years, and received 5.0 (2.8) and 4.2 (2.3) previous CIU/CSU medications, respectively. Except for one adult, all patients received antihistamines. Concomitant medications included: H 2 -receptor antagonists (overall, 48.4%; adolescents, 48.7%); LTRA (34.5%; 35.9%) and steroids (45.7%; 33.3%). CONCLUSIONS: Understanding the clinical profile of CIU/CSU in adolescents will guide clinical practice. Abstracts AB129SUNDAY
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.